Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ACTIVE NOT RECRUITING
NCT05347225
PHASE1

A Study of Nemtabrutinib (MK-1026) in China Participants With Relapsed or Refractory Hematologic Malignancies (MK-1026-005)

Sponsor: Merck Sharp & Dohme LLC

View on ClinicalTrials.gov

Summary

The purpose of this study is to evaluate the safety, pharmacokinetics (PK) and preliminary efficacy of oral nemtabrutinib in Chinese participants at least 18 years of age who have Relapsed/Refractory hematologic malignancies.

Official title: A Phase 1 Clinical Study to Investigate the Safety, Pharmacokinetics and Efficacy of MK-1026 in China Participants With Relapsed or Refractory Hematologic Malignancies

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

12

Start Date

2022-06-09

Completion Date

2027-04-30

Last Updated

2025-08-15

Healthy Volunteers

No

Interventions

DRUG

Nemtabrutinib

Nemtabrutinib tablets will be administered orally QD.

Locations (5)

Guangdong Provincial People's Hospital-hematology department ( Site 1002)

Guangzhou, Guangdong, China

SUN YAT-SEN UNIVERSITY CANCER CENTRE-Internal medicine ( Site 1007)

Guangzhou, Guangdong, China

Henan Cancer Hospital-hematology department ( Site 1003)

Zhengzhou, Henan, China

Hunan Cancer Hospital ( Site 1004)

Changsha, Hunan, China

Institute of hematology&blood disease hospital-Hematology ( Site 1001)

Tianjin, Tianjin Municipality, China